Summary (tl;dr)

Polycystic Ovary Syndrome (PCOS), a common hormonal disorder affecting millions of women globally, has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) to better reflect its complex, multisystem nature beyond just the ovaries.

Essential Background

For decades, Polycystic Ovary Syndrome (PCOS) has been a recognized condition, impacting approximately 1 in 8 women worldwide and often leading to symptoms like irregular periods, infertility, and metabolic issues. However, the term "polycystic" in its name has been widely considered inaccurate and misleading by both patients and medical professionals. This is because many patients with the condition do not actually have ovarian cysts, and the term mistakenly suggested it was primarily a gynecological issue rather than a broader hormonal and metabolic disorder. This misnomer contributed to delayed diagnoses, fragmented care, and a lack of understanding of its full health implications. Discussions and efforts to change the name have been ongoing for over a decade, with extensive patient and professional consultation.

The Full Story

On May 12, 2026, a landmark global consensus study published in The Lancet officially announced the renaming of Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This new name was simultaneously unveiled at the European Congress of Endocrinology in Prague. The initiative to change the name was spearheaded by Professor Helena Teede, an endocrinologist and director of the Monash Centre for Health Research & Implementation in Australia, following a 14-year collaborative effort involving international societies, patient groups, and over 14,000 survey responses from around the world. The change aims to provide a more accurate and comprehensive description of the condition, emphasizing its polyendocrine (multiple hormonal) and metabolic complexities, rather than solely focusing on the ovaries.

Why It Matters

The renaming of PCOS to PMOS is a significant development expected to revolutionize diagnosis, treatment, and public awareness for the more than 170 million individuals affected globally. By accurately reflecting the condition's multisystem nature—including its impacts on endocrine, metabolic, reproductive, dermatological, and psychological health—the new name is anticipated to lead to earlier and more accurate diagnoses, as well as more holistic and integrated care. It addresses the historical misconception that the disorder is purely gynecological or defined by ovarian cysts, which are often absent and not true cysts. This shift in terminology is also expected to drive increased research funding and policy framing, ultimately improving the long-term health outcomes and quality of life for those living with PMOS. The new name will be fully implemented into international guidelines by 2028.

Geographic Location

• Prague, Czech Republic (Announcement of the new name at the European Congress of Endocrinology)
• Melbourne, Victoria, Australia (Professor Helena Teede, director of the Monash Centre for Health Research & Implementation, spearheaded the name change)
• Washington, D.C., District of Columbia, United States (The Endocrine Society, a global organization, participated in the consensus process)
• Oulu, Northern Ostrobothnia, Finland (Dr. Terhi Piltonen of the University of Oulu was a lead author of The Lancet paper detailing the name change)